Heart and vascular health guide

Which distinctions matter for this goal?

Cards distinguish blood pressure, LDL, triglycerides and clinical events. Semaglutide and liraglutide are medicines studied in selected patient populations, not vitamins or general heart-support supplements. The list should not be used to change an existing treatment.

A blood marker is not a cardiovascular event

Changes in triglycerides, LDL cholesterol or blood pressure concern risk markers. Reducing heart attacks, strokes or deaths is a different question, usually requiring longer follow-up. A biomarker result on a card does not establish fewer cardiovascular events overall. This distinction is particularly important for omega-3 research: NIH ODS describes trials using different populations and formulations, without identical results in every setting. ^[1]

A high-risk group with elevated triglycerides already receiving medicines is not equivalent to a general-population primary-prevention trial. Absolute benefit depends on baseline risk; a percentage without the population and comparator can mislead.

Separate prescription products from fish-oil supplements

A finding with purified prescription EPA cannot be transferred directly to ordinary fish-oil products containing different EPA/DHA ratios. Observational evidence about eating fish is also not a capsule trial. Read the amount, formulation, accompanying treatment and measured outcome together. Increased atrial fibrillation risk in some high-dose omega-3 studies shows why benefits and harms must be considered together. ^[1]

Cards therefore keep an outcome-specific assessment instead of labeling an entire substance as “good” or “bad” for the heart. Prescription medicines appearing here are not products to use as ordinary supplements.

Potassium: diet and safety boundaries

The relationship between potassium intake and blood pressure does not mean everyone should take potassium supplements. The kidneys regulate potassium balance; excess accumulation can be dangerous with kidney disease or certain medicines. NIH ODS describes this risk with ACE inhibitors, angiotensin receptor blockers and potassium-sparing diuretics. Potassium-containing salt substitutes also matter. ^[2]

Start with the outcome you want to understand, your existing condition and treatment, and then the preparation studied. An improved laboratory marker is not a reason to independently stop treatment. This guide does not recommend personal medicine or dose changes.

A trial example: prescription EPA and absolute differences

REDUCE-IT studied prescription icosapent ethyl in 8,179 high-risk patients taking statins with elevated triglycerides. Over a median 4.9 years, the composite cardiovascular event rate was 17.2% versus 22.0% with placebo: an absolute difference of 4.8 percentage points. Hospitalization for atrial fibrillation/flutter also increased (3.1% versus 2.1%). This industry-funded trial cannot be transferred directly to ordinary fish oil or healthy, low-risk people. ^[3]

Start with overall risk management

NHLBI describes cardiovascular care as a plan combining diet, physical activity, stopping smoking and medicines when needed. Blood pressure, cholesterol and diabetes management are part of that plan. Established coronary disease and risk factors alone may call for different approaches. ^[4]

After asking which measurement changes, ask whether hospitalizations or events were studied in people with similar risk. This comparison puts research into context; it is not a reason to discontinue treatment. The blood glucose guide provides a separate framework for glucose outcomes.

Which symptoms should not wait?

New chest pain or pressure, breathlessness, cold sweats or discomfort spreading to the arm or jaw may indicate a heart attack. Symptoms can begin mildly. Seek emergency help rather than trying a supplement. ^[5]

Summary: which outcome, which limitation?

Detailed compound guides

• Omega-3: High triglycerides (prescription-level doses); Cardiovascular events and death in the general adult population — no benefit shown.
• Psyllium (Plantago fiber): LDL cholesterol reduction.
• Coenzyme Q10: Heart failure (in addition to standard treatment); Blood pressure — systolic reduction in cardiometabolic patients.
• Potassium: Blood pressure — small reduction in people with high blood pressure; Potassium salt substitution — stroke and death (China, rural; single RCT).
• Berberine: Cholesterol and triglycerides — small decrease, high heterogeneity.
• Folic Acid: Lowering homocysteine level; Heart attack and death risk — no benefit shown.
• Semaglutide: Cardiovascular events (high-risk groups).
• Liraglutide: Type 2 diabetes and high cardiovascular risk: major cardiovascular events.